Answers are grounded in this paper and cite their sources.
Clinical evaluation reveals improved outcomes with perioperative nivolumab in resectable non-small-cell lung cancer, suggesting added benefits from adjuvant phases.
Standard treatment with neoadjuvant nivolumab plus chemotherapy significantly improves outcomes in patients with resectable non-small-cell lung cancer (NSCLC). Perioperative treatment (i.e., neoadjuvant therapy followed by surgery and adjuvant therapy) with nivolumab may further improve clinical outcomes.
No takes yet. Share an insight, caveat, or question.
Cascone et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: